The purpose of this study is to evaluate the safety and performance of High-Frequency Oscillatory Ventilation (HFOV) modes of the Servo-n ventilator in neonates and infants, by using a prospective, observational, single-arm (i.e., non-controlled) and multi-center Post-Market Follow-up (PMCF) study design. HFOV treatment will be evaluated by assessing ventilation and oxygenation variables, and safety will be evaluated by documentation of device related adverse events.
The purpose of this study is to evaluate the safety and performance of HFOV modes of the Servo-n ventilator in neonates and infants. This is a prospective, observational, single-arm (i.e., non-controlled) and multi-center PMCF study in neonates and infants between 0.3 to 8 kg. All study procedures are within each hospital's routine clinical practice.The primary endpoints includes variables which are routinely used per clinical practice for assessing the status of patient's ventilation and oxygenation, respectively. Secondary endpoints are used to evaluate safety of Servo-n HFOV during its use by assessing rates of adverse event/ device deficiencies related to the Servo-n HFOV device, and by assessing rates of mortality, Bronchopulmonary Dysplasia (BPD) and Retinopathy at Intensive Care Unit (ICU) discharge. Data collection will take place up to 24 hours prior to HFOV treatment, during HFOV and up to ICU discharge. Additional general data such as ventilator settings, reasons for initiating/terminating HFOV treatment and demographics will also be recorded.
Study Type
OBSERVATIONAL
Enrollment
75
Treatment with high frequency oscillatory ventilation with Servo-n device in accordance to Standard of Care
CHU Montpellier-Arnaud de Villeneuve
Montpellier, France
RECRUITINGAntoine-Béclère Hospital
Paris, France
RECRUITINGPoznan University of Medical Sciences
Poznan, Poland
RECRUITINGUniversity Hospital of Geneva (HUG),
Geneva, Switzerland
RECRUITINGProportion of subjects that achieved and/or maintained target ranges for oxygenation, as measured by preductal Saturation of Peripheral Oxygen (SpO2).
Oxygenation response, elective HFOV patients
Time frame: After Servo-n HFOV treatment, expected treatment duration 1-30 days
Proportion of subjects that achieved and/or maintained target ranges for ventilation as measured either by Partial Pressure of Carbon Dioxide (PCO2) (if available blood gas) or Transcutaneous Carbon Dioxide (TcCO2)
Ventilation response, elective HFOV patients
Time frame: After Servo-n HFOV treatment, expected treatment duration 1-30 days
Proportion of subjects that maintained or improved values for oxygenation as measured by the SpO2/FiO2 ratio and/ or achieved target ranges for oxygenation (preductal SpO2)
Oxygenation response, rescue HFOV patients
Time frame: After Servo-n HFOV treatment, expected treatment duration 1-30 days
Proportion of subjects that maintained or improved values, and/or achieved target ranges, for ventilation as measured either by PCO2 (if available blood gas) or TcCO2.
Ventilation response, rescue HFOV patients
Time frame: After Servo-n HFOV treatment, expected treatment duration 1-30 days
The occurrence of reported Servo-n HFOV device (including accessories) deficiencies and adverse device effects and serious adverse device effects (ADE and SADE)
Device deficiencies and adverse events
Time frame: After Servo-n HFOV treatment, expected treatment duration 1-30 days
Patient outcome at ICU discharge
Events to be noted are: death caused by respiratory failure, death caused by circulatory failure, all-cause death, device related death, retinopathy and bronchopulmonary dysplasia
Time frame: Through study completion (at ICU discharge), expected up to 120 days
Assessment of oxygenation status
Oxygen Saturation (SO2)
Time frame: From available blood gas and at Baseline (-4h -2h, -1h, 0h), During HFOV (0h, 30min, 1h, 2h, 4h, 6h. etc every 6 h), Post HFOV (2h, 4h, 6h, 12h and 24h)
Assessment of ventilation status
Partial pressure of CO2 (PCO2)
Time frame: From available blood gas and at Baseline (-4h -2h, -1h, 0h), During HFOV (0h, 30min, 1h, 2h, 4h, 6h. etc every 6 h), Post HFOV (2h, 4h, 6h, 12h and 24h)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.